US2023181567A1PendingUtilityA1

Liposomes Useful for Drug Delivery

86
Assignee: IPSEN BIOPHARM LTDPriority: May 3, 2004Filed: Nov 17, 2022Published: Jun 15, 2023
Est. expiryMay 3, 2024(expired)· nominal 20-yr term from priority
Inventors:Keelung HongDaryl C. DrummondDmitri B. Kirpotin
A61P 35/00A61P 31/12A61K 45/06Y10S977/907A61K 31/475A61K 47/10A61K 9/0019Y10S977/773A61K 9/50A61K 31/4375A61K 31/337A61P 43/00A61K 31/704A61K 47/24A61K 9/1271A61K 47/50A61K 31/4745A61P 31/04A61K 47/6913A61K 9/127C07H 13/12Y10S977/906A61K 47/28A61K 47/36A61K 47/26A61K 47/30A61K 47/60A61K 9/1277A61K 9/1278C07K 14/245C07K 7/08A61K 38/00A61P 1/00A61K 38/10C07K 7/06A61P 35/04A61P 35/02A61P 29/00A61P 27/16A61P 25/28A61P 25/24A61P 25/22A61P 25/20A61P 25/18A61P 25/04A61P 25/00A61P 15/10A61P 13/12A61P 13/08A61P 13/00A61P 11/06A61P 11/00A61P 9/10A61P 9/04A61P 9/00A61P 7/10A61P 5/50A61P 3/12A61P 3/10A61P 3/04A61P 3/00A61P 1/18A61P 1/16A61P 1/14A61P 1/12A61P 1/10A61P 1/08A61P 1/04
86
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled) 
     
     
         21 . A pharmaceutical composition comprising irinotecan liposomes encapsulating the irinotecan and a polyphosphate having 13-18 phosphate units per polyphosphate molecule, wherein the millimoles of irinotecan per gram of total liposomal lipids is between 0.8 and 1.7. 
     
     
         22 . The composition of  claim 21 , comprising a lecithin and cholesterol. 
     
     
         23 . The composition of  claim 22 , wherein the lecithin:cholesterol molar ratio is 3:2. 
     
     
         24 . The composition of  claim 21 , comprising DSPC and cholesterol in a 3:2 molar ratio. 
     
     
         25 . The composition of  claim 21 , comprising DSPC, cholesterol, and an amphipathic polymer comprising a polyethylene glycol-lipid. 
     
     
         26 . The composition of  claim 25 , wherein the polyethylene glycol-lipid is a polyethylene glycol phosphatidylethanolamine. 
     
     
         27 . The composition of  claim 26 , wherein the polyethylene glycol phosphatidylethanolamine has a poly(ethylene glycol) moiety having a molecular weight ranging from about 250 to about 20,000. 
     
     
         28 . The composition of  claim 21 , comprising DSPC, cholesterol, and N-(methoxy-poly(ethylene glycol)-oxycarbonyl)-di stearoylphosphatidylethanolamine, in a molar ratio of 3:2:0.015. 
     
     
         29 . The composition of  claim 21 , comprising DSPC, cholesterol, and methoxy-PEG(2000)-DSPE, in a molar ratio of 3:2:0.015. 
     
     
         30 . The composition of  claim 21 , comprising one or more phospholipids, and wherein the liposomes encapsulate irinotecan and a polyphosphate having 13-18 phosphate units per polyphosphate molecule, and the ratio of grams of irinotecan to moles of total phospholipids is (134.4±9.3):1. 
     
     
         31 . The composition of  claim 21 , comprising one or more phospholipids, and wherein the liposomes encapsulate irinotecan and a polyphosphate having 13-18 phosphate units per polyphosphate molecule, and the ratio of grams of irinotecan to moles of total phospholipids is (162.4±4.0):1. 
     
     
         32 . The composition of  claim 21 , wherein the millimoles of irinotecan per gram of total liposomal lipids is between 0.8 and 1.3.

Join the waitlist — get patent alerts

Track US2023181567A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.